Implantable collamer lens. What the literature actually says.
For corneas the laser cannot safely correct. A short, honest read on EVO/EVO+ ICL outcomes, the endothelial-cell-loss trajectory, and why the central-port design changed the safety conversation. Every claim links to the paper.
What it is.
An implantable collamer lens (ICL) is a phakic intraocular lens — a soft, foldable lens inserted into the posterior chamber between the iris and the patient's natural crystalline lens. The native lens is not removed; the ICL adds refractive power. The procedure exists for refractive errors outside the safe envelope of laser surgery: very high myopia (typically beyond −8.00 to −10.00 D), thin corneas, irregular topography that fails refractive-surgery screening, or dry-eye profiles where ablation is contraindicated.
The modern STAAR EVO/EVO+ Visian ICL (the V4c platform) carries a central 0.36 mm port — the KS-AquaPORT — that allows aqueous humour to flow without an iridotomy. The central port is the technical change that transformed ICL safety: the older non-port designs caused enough pupillary block and anterior subcapsular cataract to limit the procedure to specialist centres. The V4c data has redrawn that envelope.
The technique.
An ESCRS-credentialed refractive surgeon screens for ICL with anterior-segment OCT (anterior chamber depth, sulcus-to-sulcus distance, white-to-white), endothelial cell density specular microscopy, tomography, and detailed refraction. Sizing is the operative variable — the lens must vault between 250 and 750 microns over the native crystalline lens. Below 250 microns increases cataract risk; above 750 microns increases angle closure and pigment-dispersion risk.
Implantation is performed through a 3 mm clear-corneal incision under topical anaesthetic. The folded ICL is loaded into an injector cartridge, advanced through the incision and into the posterior chamber, where it unfolds and is positioned with each haptic in the ciliary sulcus. The central port eliminates the need for a pre-operative peripheral iridotomy that the older V4 design required. Total room time is 30 minutes per eye in our protocol.
Vision is functional within 4-24 hours; refraction stabilises within the first week. The patient receives a topical antibiotic, topical steroid, and topical anti-hypertensive for the first 24 hours to manage post-operative pressure spikes that can occur with the early-phase ICL.
What the outcomes data shows.
Visual efficacy is excellent. The 2018 Packer review (Clinical Ophthalmology, 67 preclinical and clinical studies, 1,905 eyes effectiveness and 4,196 eyes safety) characterises the V4c platform as safe and effective across a broad refractive range, with reduced anterior subcapsular cataract and pupillary block rates versus older models. A 10-year follow-up by Alfonso-Bartolozzi et al. (Journal of Cataract & Refractive Surgery, 2024, n=127 eyes including 37 low-vault) reports no cases of ICL-induced anterior subcapsular cataract over the decade — central-port design is protective even at low vault values.
Endothelial cell loss is the honest counterweight. A 2024 meta-analysis by Kisiel et al. (Journal of Cataract & Refractive Surgery, 18 studies) reports mean ECD loss of 1.32% at 3 months, 1.75% at 12 months, and 3.84% at approximately 21 months — with the loss being most pronounced acutely, suggesting surgical trauma rather than ongoing lens-induced damage. Long-term cohorts report cumulative annual loss of roughly 1.1% per surgical eye versus 0.5% per non-surgical eye over 12 years — a real differential the patient deserves to know.
Vault behaviour and the risk-curve at either tail is now well-mapped. Vault <250 microns correlates with elevated cataract risk in older designs; the V4c central-port studies (including a 2023 paper showing low vaults averaging 52 microns over 5.8 years) suggest the port mitigates but does not eliminate this risk. Vertical rotation of the ICL is the standard management when an oversized lens produces excessive vault — characterised by Matarazzo et al. (International Ophthalmology, 2018) — avoiding lens exchange in most cases.
What we still study.
Long-term endothelial trajectory beyond 15-20 years is the open question. The V4c platform is approximately 15 years old in routine clinical use; the data on what happens to endothelial cell density at 20-30 years — when patients implanted in their twenties reach middle age and may need future intraocular surgery — is still being accumulated. Patients with borderline pre-operative ECD or anatomical risk factors (shallow anterior chamber, ageing endothelium) warrant a careful long-horizon conversation at consent.
Vault prediction is the active area of pre-operative refinement. AI-based tools for vault prediction (a 2025 PMC paper evaluating predictive accuracy) are beginning to outperform legacy sizing nomograms; whether they will produce a measurable reduction in the rare 0 µm-vault complication remains under study.
The Hektor protocol.
Pre-operative screen includes anterior-segment OCT for sulcus-to-sulcus measurement, specular microscopy for endothelial cell density (we decline ICL below an age-adjusted ECD threshold), tomography, and detailed refraction. Sizing uses the STAAR EVO+ nomogram cross-checked against an anterior-segment OCT-derived calculation; a borderline sulcus dimension results in a no rather than an at-risk implantation.
Cases run on the STAAR EVO+ V4c platform — 30 minutes per eye, both eyes consecutive or staged based on patient preference. Daycase suite, discharge the same afternoon. Structured video review at 24 hours, 1 week, 1 month, 3 months, 12 months, with annual endothelial cell counts thereafter — that long-term endothelial accounting is part of the package.
- ·High myopia outside the safe envelope of laser surgery (typically beyond −8.00 to −10.00 D, up to approximately −18.00 D)
- ·Thin corneas where LASIK or SMILE residual-bed prediction is unsafe
- ·Irregular topography that fails refractive-surgery screening but is otherwise visually correctable
- ·Significant dry eye or autoimmune profile where corneal ablation is contraindicated
- ·Patients who specifically want a reversible refractive solution
- ·Adequate anterior chamber depth (typically ≥2.8 mm from endothelium) and sulcus dimensions
- ·Endothelial cell density above an age-adjusted floor (specular microscopy mandatory)
- ·Age 21–45 typically (younger requires stable refraction; older approaches lens-based-surgery territory)
- —Endothelial cell density below the age-adjusted floor (specular microscopy decides)
- —Shallow anterior chamber, narrow angles, or anatomy that does not support safe vault
- —Active uveitis, untreated glaucoma, or pigment-dispersion syndrome
- —Visually significant cataract (cataract surgery with IOL is the indicated procedure instead)
- —Pregnancy or breastfeeding (refraction can shift transiently)
- —Unrealistic expectations on long-term endothelial trajectory or unwillingness to commit to annual specular microscopy follow-up
- —Borderline sulcus measurement where vault prediction falls outside the 250–750 micron safe window
Borderline anterior chamber depth or borderline ECD: declined cleanly. The endothelium does not regenerate; a marginal pre-op count rules out ICL rather than 'we'll watch it'.
High myopia with otherwise excellent corneal anatomy: laser surgery (LASIK or SMILE) is often the cleaner answer up to its safe envelope. ICL is the right answer when the cornea is the constraint, not the prescription alone.
Patients approaching presbyopia (40+): we discuss honestly that ICL corrects distance but does not solve presbyopia, and that refractive-lens-exchange with a premium IOL may be the better long-term answer despite being non-reversible.
Recovery, by milestone.
Compared to alternatives.
For corrections within the laser envelope and a robust cornea, LASIK is simpler, cheaper, and has 20+ years of long-term safety data. ICL becomes the better answer when the cornea cannot safely accept laser ablation — high prescription, thin pachymetry, irregular topography, or significant dry eye.
SMILE is corneal, ICL is intraocular — different organ. For corrections SMILE can safely deliver, SMILE preserves the natural intraocular environment and avoids any endothelial-loss conversation. ICL takes over above the SMILE envelope or where the cornea is the constraint.
RLE removes the natural crystalline lens — irreversible, but solves presbyopia at the same time. ICL preserves the natural lens (reversible) but does not address presbyopia. For patients in their 20s and 30s, ICL is usually the right answer; for patients 45+ with early presbyopia, RLE with a premium IOL is often the better long-term solution.
For high myopia, glasses are heavy and contact-lens dependence over decades carries its own corneal-health cost. ICL is a meaningful lifestyle change. The honest counterweight is the cumulative ~1.1% per year endothelial cell loss versus ~0.5% per year for a non-surgical eye over 12 years — a real trade-off disclosed at consent.
- ·Bilateral ICL implantation (both eyes; consecutive or staged based on patient preference)
- ·Pre-op screen: anterior-segment OCT (sulcus-to-sulcus, anterior chamber depth), specular microscopy (endothelial cell density), Pentacam tomography, manifest + cycloplegic refraction
- ·STAAR EVO+ V4c lens (toric included when indicated)
- ·Post-op medication kit (topical antibiotic, steroid, short anti-hypertensive)
- ·24-hour video check with the operating surgeon before your flight
- ·Structured follow-up at week 1, month 1, month 3, and month 12
- ·Annual specular microscopy review for endothelial-cell tracking (year 1 onward)
- ·Translator (8 languages) + airport transfers + optional hotel night
Ranges are per eye to match how UK/US/EU clinics publish ICL pricing. Sourced from publicly published 2025–2026 clinic price pages.
Our Istanbul figure is a locked per-eye package. Toric ICL for astigmatism correction does not trigger a separate per-eye surcharge.
Annual specular microscopy follow-up is recommended for the life of the implant. Hektor includes the first year; subsequent annual checks can be performed locally with a copy of the chart sent to us if requested.
Common questions.
Is ICL really reversible?+
How significant is the endothelial cell loss?+
What does the central port do?+
Will ICL give me cataract?+
What is 'vault' and why does it matter?+
How long is the long-term safety data?+
Does ICL hurt?+
Will I be free of glasses forever?+
Why is Istanbul cheaper than the UK or US for ICL?+
How long do I need to stay in Istanbul?+
Book this procedure.
A specialist-signed plan in 24 hours, with the bibliography for your specific candidacy attached. The deposit holds the day; the package is one number.
Book a day